Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.